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This report describes a case of a patient with a large solid gallbladder adenocarcinoma that was completely resected
through aggressive surgery. The patient was a 57-year-old woman who had been diagnosed with advanced gallbladder
cancer, had no indications for surgical resection and was scheduled to undergo systemic chemotherapy. She presented
to our hospital for a second opinion. At the time of assessment, her tumor was large but was well-localized and had
not invaded into the surrounding tissues, indicating that surgical resection was a reasonable option. Subsequently, the
tumor was completely extracted via right hepatectomy with en bloc resection of the caudate lobe and extrahepatic
bile duct. Histopathologically, the tumor was a solid adenocarcinoma. Although there are relatively few reports in
the literature regarding solid gallbladder adenocarcinoma, well-localized growth appears to be a characteristic
feature. On the basis of a tumor’s progression behavior, aggressive surgical treatment might be indicated even
when the tumor has grown to a considerable size.
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Some gallbladder cancers (GBCs) do not show invasive
behavior, even when the tumors grow large, and these
types of tumors are associated with better outcomes
than tumors that do show invasive behavior. Surgery is
the only curative modality for GBC, whereas nonsurgical
therapies (for example, chemotherapy (cisplatin and gem-
citabine) as first-line chemoradiotherapy) can provide
limited survival benefit [1]. Therefore, it is of critical
importance to detect these well-localized GBCs via im-
aging and to proceed with appropriate surgical resection.
Elevated expression of CDX2 and hepatocyte antigen
(Hep) in GBC is associated with less aggressive behavior
[2], and activating mutations in KRAS are associated with
more malignant behavior [1,3,4]. Use of this molecular
information might allow for better estimation of prognosis
and to help guide personalized surgical therapy.* Correspondence: s-hayama@par.odn.ne.jp
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A 57-year-old woman presented to a hospital other than
ours, complaining of icterus. She was diagnosed with
advanced GBC. The surgeons there thought an operation
was not indicated, and she was scheduled to be initiated
on systemic chemotherapy. However, she presented to our
hospital for a second opinion. Abdominal computed
tomography demonstrated a large tumor in the neck
and body of the gallbladder, with expansive growth and
compression of the portal vein, common bile duct (CBD),
liver bed and inferior vena cava. However, the tumor did
not invade into these tissues (Figure 1A,B). The tumor
extended to the bile duct, resulting in obstructive jaundice;
therefore, the likely cause of tumor extension was tumor
thrombus, cancer invasion or longitudinal tumor spread
along the biliary tree. Regardless, preoperative differ-
entiation between these possibilities was impossible
(Figure 1C). There was no sign of metastasis to the liver,
peritoneum, or paraaortic lymph nodes. Taken together,
these radiological findings suggested that this large tumor
was potentially resectable.l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Abdominal computed tomography scans reveal a large, centrally necrotizing and well-demarcated tumor. (A) The tumor
compressed the neighboring tissue Yellow arrowheads indicates the inferior vena cava. (B) Yellow arrowheads indicate the right intrahepatic Glisson.
(C) Endoscopic retrograde cholangiopancreatography reveals that the tumor extended to the intrapancreatic bile duct (arrows in B and C).
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resection was considered to be the most appropriate
surgical procedure. Therefore, to prevent postoperative
liver failure, preoperative right portal vein embolization
(PVE) was performed, and the patient underwent radical
surgery 3 weeks after PVE.
At laparotomy, a large, soft tumor was palpable in the
neck and body of the gallbladder. The tumor compressed,
but did not seem to infiltrate, the surrounding gallbladder
tissues (Figure 2A). A right hepatic lobectomy with en bloc
resection of the caudate lobe and the extrahepatic bile
duct was performed. Because of tumor extension, the
extrahepatic duct was resected up to the intrapancreatic
portion, and, on the hepatic side, hepatic duct was
resected to the most peripheral point where the hepatic
ducts could be separated from the vasculature during theFigure 2 Intraoperative findings. The large and soft gallbladder (GB) tum
hepatic lobectomy with en bloc resection of the caudate lobe and extrahep
and B3, Lateral superior and inferior ducts; B4 (a and b), Medial segmental
Common bile duct; RHA, right hepatic artery; RPV, Right portal vein.right hepatectomy. This is the limit of ductal resection [5]
to ensure negative margins (Figure 2B).
The macroscopic view of the cut specimen revealed a
large tumor with central necrosis and measuring 10.7 ×
10 cm in size. The resected tumor was well-demarcated
and did not invade into the surrounding tissues. The
tumor necrotic tissue extended from the tumor up to
the intrapancreatic bile duct, which was also completely
resected (Figure 3A,B).
Histopathologically, atypical cells with an eosinophilic
and granular cytoplasm formed solid nests without tubular
structures. These cells had a large and eccentric nucleus
and a prominent nucleolus (Figure 4A,B). Immunohisto-
chemically, the tumor cells were positive for Hep and
pan-cytokeratin, but negative for α-fetoprotein. The
highest Ki-67 index was 20% in the tumor. Tumor invasionor was palpable (A). The tumor was completely removed via right
atic bile duct (B). B1(r and l), Caudate lobe duct (right and left); B2
duct (inferior and superior branches); Br, Right hepatic duct; CBD,
Figure 3 Macroscopic view of the cut specimen revealed a centrally necrotizing tumor that was 10.7 × 10 cm in size. The patient’s
gallbladder (GB) tumor compressed adjacent tissues and organs but did not invade into them (A). RHA, right hepatic artery; RPV, Right portal
vein. Tumor necrotic tissue that extended to the intrapancreatic bile duct (Bi) was also completely resected (B) CBD, Common bile duct.
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invasion or perineural invasion was identified. The
necrotic tissue extended to the biliary tract via the cys-
tic duct, but no tumor cells replaced epithelial cells of
the cystic duct or biliary tract. Therefore, a diagnosis of
tumor thrombus extending from the tumor was made.
The histopathologic diagnosis was solid adenocarcinoma
of the gallbladder, and en bloc R0 resection was confirmed
histopathologically. The tumor-node-metastasis classifi-
cation according to the Union for International Cancer
Control [6] system was pT2, pN0, M0, pStage IB.
The patient had an uneventful postoperative recovery
and was discharged from the hospital on the 22nd postop-
erative day. She received neither adjuvant chemotherapy
nor radiation therapy. Two years after the operation, she
was in good health, with no signs of recurrence.Figure 4 Photomicrographs showing the histopathologic appearance
cells formed solid nests (hematoxylin and eosin stain (H&E); original magni
prominent nucleolus (H&E stain; original magnification, ×100) (B).Discussion
Solid adenocarcinoma of the gallbladder, originally classi-
fied as a category of poorly differentiated adenocarcinoma,
has been reclassified as a distinct entity according to the
Japanese Society of Biliary Surgery classification system
(4th edition) [7]; however, this neoplasm has not been
classified by the World Health Organization [8]. Histo-
pathologically, this neoplasm is composed of tumor cells
with atypical nuclei and an eosinophilic cytoplasm, and
these cells form solid nests [9].
In the present case, the patient had a large tumor with
marked central necrosis and expansive growth. In general,
these features are typical of undifferentiated gallbladder
carcinoma [10]. Surgical treatment is not likely to be cura-
tive for such a large, undifferentiated carcinoma, as these
tumors are often associated with distant metastasis or aof atypical cells with an eosinophilic granular cytoplasm. These
fication, ×40) (A). The cells had a large and eccentric nucleus and a
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for advanced, undifferentiated gallbladder carcinoma is
only 18% [11]. Therefore, diagnostic differentiation of
undifferentiated gallbladder carcinoma and other histo-
logical types is essential.
The tumor in our patient had radiological features that
made it difficult to distinguish from undifferentiated car-
cinoma; consequently, surgery was not initially thought
to be indicated. However, detailed review of the radio-
logical and intraoperative findings showed that the
tumor had not invaded to nearby tissues, indicating that
radical surgery was an appropriate management option.
Such expansive tumor growth with a well-demarcated
margin is a characteristic feature of solid gallbladder
adenocarcinoma, as described in several reports and
presentations [12,13].
The histological type of GBC is a significant predictor
of outcome. For example, papillary adenocarcinoma and
well-differentiated adenocarcinoma are associated with
better outcomes than undifferentiated adenocarcinoma
and poorly differentiated carcinoma [11,14,15]. Further,
solid gallbladder adenocarcinoma is associated with
better postoperative outcomes than poorly differentiated
gallbladder adenocarcinoma. Although there has been
only one study with regard to survival for solid gallblad-
der adenocarcinoma, the reported 1- and 3-year survival
rates were 53.8% and 17.9%, respectively, for solid gall-
bladder adenocarcinoma and 37.5% and 0%, respectively,
for poorly differentiated gallbladder adenocarcinoma [16].
Moreover, a solid adenocarcinoma may show a spectrum
of malignancy because it is sometimes heterogeneous and
contains foci of poorly differentiated adenocarcinoma [9].
Therefore, in pure solid gallbladder adenocarcinoma (as
in our patient), favorable postoperative outcomes would
be expected. However, for more proper indicators of the
surgical prognosis in this neoplasm, a better comprehen-
sion of cellular and molecular pathogenesis is required,
which could also lead to the potential utility of targeted
therapies, as reported in PIK3CA and ALK mutations
[3,4]. To date, elevated expression of CDX2 and Hep have
been reported to be associated with GBC of less aggressive
behavior [2], whereas KRAS mutation has been reported
to be associated with poor survival [4]. Interestingly, Hep
was positive in our patient. Accrual of additional analyses
of Hep expression will reveal the relatively low malignant
nature of this neoplasm.
Finally, GBCs with tumor thrombus in the CBD are
very rare [17,18]. Including the present case, two of three
cases of solid gallbladder adenocarcinoma described in
the literature were accompanied by tumor thrombus in
the CBD, which suggests that this finding may be a
characteristic feature of this neoplasm. However, pre-
operative differential diagnosis of tumor thrombus due
to cancer invasion or intraepithelial cancer spreadalong the biliary tree remains difficult. In patients with
intraepithelial cancer spread, the margin of the cancer is
sometimes hard to characterize preoperatively. Therefore,
to ensure ductal negative margins in our patient, the
extrahepatic duct was resected as peripherally as possible.
Conclusions
In this report, we describe a case of a patient with large,
centrally necrotizing but well-localized GBC. Clinicians
should be aware that some GBCs do not show invasive
behavior, even when the tumors grow large in size, and
that these tumor types are associated with better out-
comes than tumors that do show invasive behavior. Solid
gallbladder adenocarcinoma likely constitutes one of the
histologic types of such a resectable GBC. As in the
present case, complete resection of a pure solid gallbladder
adenocarcinoma can presumably lead to long-term survival.
More detailed analysis of the molecular pathogenesis of
gallbladder adenocarcinoma might enable characterization
of the clinicopathological features of this neoplasm and the
potential utility of targeted therapies.
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